Clinical Trial Update: Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) [Phase 2]

View source ↗

Summary

A Phase 2 trial (APICAL-GC) is evaluating first-line combination therapy with anlotinib and toripalimab for advanced gastric cancer in patients with ECOG 2, cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Gastric Cancer, Immunotherapy | Phase 2 | Status: RECRUITING